Combined PLK1 and EGFR inhibition as initial treatment for EGFR-mutant NSCLC might thus prevent the emergence of an array of different constitutive resistance mechanisms rather than remedy this complexity later. Here, EGFR is linked to non-small cell lung carcinoma.